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Abstract: Background. Despite considerable interest in the search for a spinal cord injury (SCI)
therapy, there is a critical need to develop a panel of diagnostic biomarkers to determine injury
severity. In this regard, there is a requirement for continuing research into the fundamental processes
of neuroinflammatory and autoimmune reactions in SCI, identifying changes in the expression of
cytokines. Methods. In this pilot study, an extended multiplex analysis of the cytokine profiles in
the serum of patients at 2 weeks post-SCI (n = 28) was carried out, together with an additional
assessment of neuron-specific enolase (NSE) and vascular endothelial growth factor (VEGF) levels
by enzyme-linked immunosorbent assay. A total of 16 uninjured subjects were enrolled as controls.
Results. The data obtained showed a large elevation of IFNγ (>52 fold), CCL27 (>13 fold), and CCL26
(>8 fold) 2 weeks after SCI. The levels of cytokines CXCL5, CCL11, CXCL11, IL10, TNFα, and MIF
were different between patients with baseline American Spinal Injury Association Impairment Scale
(AIS) grades of A or B, whilst IL2 (>2 fold) and MIP-3a (>6 fold) were significantly expressed in the
cervical and thoracic regions. There was a trend towards increasing levels of NSE. However, the
difference in NSE was lost when the patient set was segregated based on AIS group. Conclusions. Our
pilot research demonstrates that serum concentrations of cytokines can be used as an affordable and
rapid detection tool to accurately stratify SCI severity in patients.
Keywords: traumatic spinal cord injury; cytokine profile; inflammation; blood serum; clinical trial
1. Introduction
Spinal cord injury (SCI) continues to be a major and pressing problem in modern
medicine [1]. To date, the treatment outcomes of patients with SCI are extremely unsatis-
factory and require the development and implementation of new therapeutic protocols.
In addition to the lack of effective therapeutic strategies, there is a need to develop a
panel of diagnostic biomarkers to determine injury severity, which could potentially have
prognostic value to aid the implementation of an optimal therapy strategy [2,3].
There are several stages in the course of SCI, each of which is characterized by certain
clinical signs and pathophysiological mechanisms. The acute period of SCI is most often
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considered to be within 3 days from the moment of injury. This period captures the phase
of primary damage, characterized by the development of pathological changes as a result of
the direct impact on the tissue of a damaging factor (e.g., mechanical injury), and is quickly
replaced by secondary damage [4,5]. It is in this subsequent subacute period (also referred
to as the early or intermediate period) that the classical picture of secondary damage
unfolds. This stage is characterized by the development of an inflammatory response,
oxidative stress and excitotoxicity, which leads to the death of neurons and glial cells, the
spread of ascending and descending tracts damage, and axon demyelination [4,6–9]. It
should be noted that secondary injury during this period leads to more serious clinical
consequences than the original primary injury [1].
Currently, there is a low rate of translation of new therapeutic approaches for SCI,
with very few studies in later stage clinical trials [10,11]. A key reason for this is the fact
that post-traumatic processes in animal SCI models can differ significantly from those
which occur in human patients [12]. Studies on animal models show that subacute SCI
promotes complex cytokine network imbalances [13,14]. In this regard, additional research
aimed at deciphering the dynamics of cytokine expression in human samples after SCI is
timely and an extremely relevant means of determining new markers of the post-traumatic
process to uncover novel therapeutic approaches, in particular, those that may reduce the
negative components of inflammatory reactions.
In addition to the search for new mechanisms upon which to base therapeutic strate-
gies, attempts are also being made to identify biomarkers of SCI severity that could predict
the outcome of the post-traumatic process [3,15]. It is considered that cerebrospinal fluid
(CSF) is more representative for SCI severity assessment given its proximity to the spinal
cord [11]. In this regard, most investigators focus on determining the post-traumatic levels
of CSF biomarkers between SCI patients with different baseline American Spinal Injury
Association Impairment Scale (AIS) grades [12,16–19]. Nonetheless, the clinical manage-
ment of SCI patients does not suggest that routine CSF collection, for which there are
contraindications and the risk of complications, is the best approach. The detection of
markers in blood serum provides an alternative and easily accessible biofluid in which to
routinely test for markers that determine SCI severity and have prognostic value.
This pilot study characterized cytokine expression at 2 weeks post-SCI in humans,
establishing any associations between the injury severity or region and the concentration of
inflammatory proteins, including additional assessment of neuron-specific enolase (NSE)
and antigenic molecule vascular endothelial growth factor (VEGF).
2. Materials and Methods
2.1. Participants Enrollment
This study was approved by the Kazan Federal University Local Ethical Committee
(Protocol No. 3, 23 March 2017). Written informed consent was obtained from each subject
before blood serum was collected. Between 2017 and 2019, data were obtained from
28 patients (16 males and 7 females) suffering from subacute traumatic SCI who were
admitted to the Neurosurgical Department No. 2 of the Republican Clinical Hospital
(Kazan, Russia).
The following inclusion criteria were used for patients with subacute SCI in this
prospective trial: (1) over 18 years of age; (2) SCI between C3 and L3 inclusive; (3) the ability
to provide a valid, reliable neurological examination; and (4) classified with an AIS grade
of A or B. Patients with concomitant traumatic brain injury, severe chest injuries, and intra-
abdominal injuries were excluded from our study. The severity of neurological impairment
with baseline AIS grade assessments were conducted by a research study neurologist
experienced in these techniques and in calculating AIS. Neurological examinations were
conducted at 1, 2, and 3 weeks post-injury to determine AIS conversion and possible motor
and sensory score improvement.
The uninjured control group consisted of blood serum samples collected from 16 healthy
able-bodied individuals, from whom we obtained consent to acquire venous blood. Un-
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injured subjects were recruited from the Kazan Federal University student and academic
population, and hospital staff. The following inclusion criteria were used for uninjured
subjects: (1) over 18 years of age; (2) without a history of SCI; (3) a lack of the main signs of
inflammation; and (4) a normal complete blood count. The exclusion criteria for uninjured
subjects were a previously established diagnosis of chronic inflammatory and autoimmune
processes or neurological disorders, including a head trauma.
2.2. Sample Acquisition
Venous blood was collected (6 mL vacuum test tube, Apexlab, Moscow, Russia) via
standard venipuncture at 2 weeks after injury. After 30 min of coagulation, the blood was
centrifuged at 3000 rmp, divided into aliquots (300 µL), and stored at −80 ◦C until analysis.
The blood serum samples of all participants were subjected to the same manipulations
and similar storage times. To achieve this, on the day of venous blood sampling from SCI
patients, venous blood sampling of uninjured individuals was also carried out in parallel.
2.3. Biochemical Analysis
In our study, we analyzed changes in the blood serum cytokine profile of SCI patients
at 2 weeks post-injury using multiplex analysis by xMAP Luminex technology. Bio-Plex
Pro™ Human Cytokine 40-plex Assay #171AK99MR2 (Bio-Rad, Hercules, CA, USA) was
used, allowing simultaneous multiplex analysis of 40 (CCL21, CXCL13, CCL27, CXCL5,
CCL11, CCL24, CCL26, CX3CL1, CXCL6, GMCSF, CXCL1, CXCL2, CCL1, IFNg, IL1b, IL2,
IL4, IL6, IL8, IL10, IL16, CXCL10, CXCL11, MCP-1, MCP-2, MCP-3, MCP-4, CCL22, MIF,
MIG, MIP-1a, MIP-1b, MIP-3a, MIP-3b, MPIF-1, CXCL16, CXCL12, CCL17, CCL25, and
TNFa) human cytokines in 50 µL of the test sample. All obtained blood serum samples
(28 from SCI patients and 16 from uninjured individuals) were analyzed together in the
same assay. We also performed standard enzyme-linked immunosorbent assay (ELISA) on
NSE (P3H 2015/2531, VectorBest, Moscow, Russia) and VEGF (P3H 2017/5974, VectorBest,
Moscow, Russia) in the same serum samples. NSE and VEGF concentrations were expressed
in pg/mL. The above assays were carried out strictly according to the manufacturer’s
instructions and each serum sample was assayed in duplicate. All biochemical analysis was
performed by investigators who were blinded to uninjured control and SCI patient groups,
as well as any knowledge of the baseline AIS grade and subsequent neurological outcome.
2.4. Statistical Analysis
R 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria) was used for data
analysis. Descriptive statistics for quantitative variables are presented as mean (standard
deviation) and median (interquartile range). Linear models with age as an adjusted
covariate were used to estimate differences in log2-transformed expression levels of target
markers. The Benjamini–Hochberg procedure was applied for multiplicity correction.
3. Results
3.1. Subject Demographics
A total of 28 subacute SCI patients were enrolled, the general demographic features
and neurological status of which are shown in Table 1. Additional information concerning
comorbidity and concurrent medication was collected from SCI patients and summarized
in Table 2. The blood serum samples from SCI patients were acquired at 2 weeks after
injury. All injured patients had stable data of AIS grade at weeks 1 to 3 post-injury (time
spent in the Neurosurgical Department), and no AIS improvement was observed in the
subacute period of SCI. In the 16 uninjured subjects, 8 were male and 8 were female with
an average age 32.7 ± 11.5 years. The uninjured individuals did not have chronic or acute
inflammatory or autoimmune conditions and did not take any medication for at least a
month before blood sampling.
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Table 1. Patient demographics and neurological status in patients 2 weeks post-spinal cord injury.
Characteristics AIS Grade A AIS Grade B
No. of subjects 22 6
Gender (Male/Female) 16/6 3/3
Age 40.2 ± 13.9 32.5 ± 6.3
Etiology







AIS—American Spinal Injury Association Impairment Scale.
Table 2. Concurrent conditions and medication history in spinal cord injury (SCI) patients 2 weeks post-injury.










Dexamethasone 4.0 i/m № 7 (3 days)
28 (22 AIS A,
6 AIS B)
Community-acquired
pneumonia 1 (AIS A)
spasmolytic drugs
Spasmalin 5.0 i/m once a day (5 days)
Tizanidine 12 mg once a day (10 days)
5 (AIS A)
1 (AIS A)
Post-traumatic pneumonia 2 (AIS A)
analgesics
Ketorol 1.0 i/m once a day (5 days)
Tramadol 50 i/m once a day (2 days)
23 (17 AIS A, 6 AIS B)
5 (AIS A)
Spondyloarthrosis 1 (AIS A)
Supportive therapy **
Anticoagulants
Enixum 0.4 once a day
24 (20 AIS A, 4 AIS B)
Smoker 5 (4 AIS A, 1 AIS B)
Antibiotics
Levofloxacin 500 mg once a day
Ceftriaxone 2.0 once a day
1 (AIS A)
2 (AIS A)
Hypertensive heart disease 1 (AIS B) HypertensionAmlodipine 5 mg once a day 1 (AIS B)
* Intensive therapy is generally carried out during the first week after SCI. ** History data collected within 5 days before blood serum
sampling. AIS—American Spinal Injury Association Impairment Scale. Groups of drugs are indicated in italics.
3.2. Multiplex Analysis of Blood Serum Cytokines
We performed simultaneous multiple cytokine analysis of the blood serum on 2 weeks
post-SCI patients and uninjured subject samples (Supplementary Table S1, Figure 1). IFNγ,
CCL27, CCL26, CXCL6, IL2, IL4, MCP-3, and MIP-3a all showed a significant elevation in
the SCI patient samples (Figure 2). The greatest difference was found for IFNγ, which was
more than ~52 times higher (FC 52.04 (39.68; 68.25), Padj = 0.0001) in SCI patients compared
to the uninjured control subjects. Large differences were also seen for CCL27 (13.10 (2.87;
59.90), Padj = 0.0044) and CCL26 (8.12 (5.79; 11.39), Padj = 0.0001) levels, which were both
elevated 2 weeks after SCI.
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Figure 1. Graphical representation showing log2 cytokine concentrations (color keys), generated with the multiplex anal-
ysis of the blood serum collected at 2 weeks post-injury (n = 28) or from uninjured controls (n = 16). A dendrogram resulting 
from hierarchical clustering of cytokines is shown on the left. 
Figure 1. Graphical representation showing log2 cytokine concentrations (color keys), generated with the multiplex analysis
of the blood serum collected at 2 weeks post-injury (n = 28) or from uninjured controls (n = 16). A dendrogram resulting
from hierarchical clustering of cytokines is shown on the left.
MIG, IL1b, and IL10 were significantly decreased at 2 weeks post-injury compared to
uninjured subject samples (Figure 2). The greatest decrease was found for IL1b (0.25 (0.18;
0.34), Padj = 0.0001) in SCI patients compared to uninjured control subjects.
3.3. Determination of the Effect of the Spinal Cord Injury Region on Blood Serum Cytokines
To determine if the region of SCI affects blood serum cytokine levels, we compared
cytokine levels when segregated based on the region of injury. SCI at cervical (C) and
lumbar (L) regions had the greatest and least impact, respectively, on the cytokine profile in
blood serum at 2 weeks post-injury. We observed a strong positive association between C
injury and CXCL1 (2.02 (1.25; 3.26), Padj = 0.0231), CXCL10 (3.13 (1.29; 7.56), Padj = 0.0465),
and CXCL11 (0.19 (0.05; 0.68), Padj = 0.0457) concentrations (Table 3). SCI at both the C
and thoracic (Th) positions produced a significant increase in IL2 and MIP-3a, as well as a
decrease in MIG concentrations at 2 weeks post-injury (Figure 3, Table 3). SCI at Th and
L regions, but not C, showed a positive association with CCL22 concentration (Table 3).
We did not find a correlation between injury regions and CCL26, CXCL6, CCL1, IFNγ,
IL10, IL1b, IL4, and MCP-3 concentrations. SCI at any region led to significant changes
in above-mentioned cytokine concentrations in the blood serum at 2 weeks post-injury
compared to uninjured control subjects.
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Table 3. Cytokine concentrations (ng/mL) in blood serum at 2 weeks post-spinal cord injury at cervical (C, n = 13), thoracic
(Th, n = 12), and lumbar (L, n = 3) regions in patients and uninjured control subjects (n = 16).
Markers Uninjured Control C Th L
CXCL1
26.80 (20.21) 47.96 (18.06) 39.12 (13.17) 31.54 (3.55)
18.16 (13.23-40.48) 46.08 (34.55-59.12) * 34.23 (29.90-45.37) 31.54 (30.29-32.80)
CXCL10
10.76 (17.69) 26.58 (31.55) 15.16 (14.05) 5.10 (0.13)
4.26 (1.79-9.72) 15.92 (6.98-26.43) * 9.36 (5.93-19.52) 5.10 (5.05-5.14)
CXCL11
72.70 (175.50) 2.01 (1.62) 2.39 (1.08) 1.00 (0.02)
2.02 (1.21-36.61) 1.52 (1.11-1.97) * 2.12 (1.80-2.71) 1.00 (1.00-1.01)
MIG
114.44 (154.44) 31.74 (19.65) 27.13 (11.64) 15.27 (7.63)
70.53 (40.30-136.70) 27.13 (16.55-44.95) * 26.45 (18.75-36.73) * 15.27 (12.57-17.96)
CCL22
10.41 (9.80) 59.53 (149.58) 24.67 (17.01) 47.52 (2.55)
7.10 (3.43-14.98) 15.77 (7.56-20.01) 16.87 (10.59-37.67) * 47.52 (46.62-48.42) *
CCL26
2.00 (1.46) 15.30 (6.07) 14.54 (7.50) 8.29 (1.51)
1.38 (0.92-2.46) 13.19 (11.11-16.84) # 12.02 (10.81-14.72) # 8.29 (7.75-8.82) **
CXCL6
2.61 (2.25) 8.88 (3.19) 8.01 (2.42) 6.60 (0.54)
2.07 (0.80-3.11) 7.58 (7.47-10.11) # 7.22 (6.98-8.62) # 6.60 (6.40-6.79) *
CCL1
3.25 (2.62) 9.63 (3.47) 7.88 (0.87) 7.30 (0.40)
1.90 (1.40-4.96) 8.55 (7.78-9.53) # 7.92 (7.58-8.36) # 7.30 (7.16-7.44) *
IFNγ
0.42 (0.20) 20.44 (6.00) 20.13 (6.46) 13.86 (3.42)
0.39 (0.24-0.60) 18.98 (17.10-21.03) # 17.38 (16.27-23.45) # 13.86 (12.65-15.06) #
IL10
12.40 (7.81) 6.41 (5.85) 3.77 (1.43) 2.71 (0.13)
12.13 (6.47-15.23) 4.97 (3.79-6.02) * 3.27 (2.74-4.99) ** 2.71 (2.67-2.76) *
IL1b
5.08 (1.67) 1.69 (1.37) 1.09 (0.46) 0.77 (0.08)
5.32 (3.77-6.51) 1.16 (1.00-1.68) # 0.93 (0.87-1.02) # 0.77 (0.74-0.80) #
IL4
1.58 (1.21) 5.87 (2.12) 4.66 (1.18) 3.93 (0.61)
0.99 (0.82-2.25) 4.87 (4.55-6.60) # 4.75 (3.81-5.25) # 3.93 (3.71-4.15) **
MCP-3
10.28 (5.16) 42.35 (14.34) 37.33 (9.59) 27.09 (7.38)
12.02 (6.15-13.56) 35.93 (34.13-50.99) # 37.09 (30.44-44.48) # 27.09 (24.48-29.70) *
* Padj < 0.05, ** Padj < 0.01, and # Padj < 0.0001 comparing to uninjured control subjects.
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3.4. Classifying Injury Severity with Blood Serum Cytokines
The cytokine data at 2 weeks post-SCI revealed differences existed between the AIS
A and B groups of patients for CXCL5, CCL11, CXCL11, IL10, TNFα, and MIF in blood
serum (Supplementary Table S1). In the AIS A patient group, an increase of CXCL5 (1.66
(1.13; 2.44), Padj = 0.0299) and TNFα (1.91 (1.12; 3.26), Padj = 0.0448), and a decrease in
CCL11 (0.44 (0.27; 0.71), Padj = 0.0055), CXCL11 (0.23 (0.08; 0.65), Padj = 0.0205), and IL10
(0.44 (0.27; 0.72), Padj = 0.0065) were found compared to uninjured controls (Supplementary
Table S1). At the same time, elevation in MIF concentration (6.83 (1.79; 26.01), Padj = 0.0193)
was observed in the AIS B patient group (Supplementary Table S1).
3.5. NSE and VEGF Blood Serum Concentration
In addition to the panel of cytokines investigated, we also determined the levels of
inflammatory protein NSE and VEGF in the blood serum by ELISA. An increase in NSE
expression (Padj = 0.0124) was determined at 2 weeks post-SCI compared to uninjured
controls (Table 4). VEGF concentration was also increased, but not at the level of significance
when compared to uninjured controls (Table 4). Despite the trend of increased NSE and
VEGF remaining the same, the significance of NSE was lost when the patient set was
segregated based on AIS group (Table 4). However, this potentially may be due to the
reduction of numbers per AIS group compared to controls (Table 4).
Table 4. Neuron-specific enolase (NSE) and vascular endothelial growth factor (VEGF) concentrations (pg/mL) in blood
serum in 2 weeks post-spinal cord injury patients and uninjured control subjects.
Markers Uninjured Control SCI AIS A AIS B
NSE
1.54 (0.80) 3.31 (3.15) 2.85 (2.51) 4.74 (4.61)
1.40 (1.10-1.62) 2.10 (1.50-3.70) * 2.05 (1.52-3.38) 3.00 (1.50-6.20)
VEGF
233.10 (220.59) 373.03 (302.61) 368.27 (282.24) 368.27 (282.24)
179.54 (75.84-356.80) 324.08 (107.85-592.85) 344.73 (111.05-587.15) 344.73 (111.05-587.15)
* Padj < 0.05 comparing to uninjured control subjects. AIS - American Spinal Injury Association Impairment Scale.
4. Discussion
In this study, using multiplex analysis of blood serum collected from SCI patients at
2 weeks post-injury (n = 28), we determined the levels of 40 cytokines and 2 additional
proteins, NSE and VEGF, compared to a cohort of uninjured subjects (n = 16). The data ob-
tained showed a large elevation of IFNγ (>52 fold), CCL27 (>13 fold), and CCL26 (>8 fold)
at 2 weeks after SCI. As IFNγ has previously been shown to be a key regulator of many cy-
tokines, the increase in IFNγ at this stage suggests the start of a process of IFNγ-dependent
cytokine modulation [20]. Th1 cells expressing IFNγ induce activation and M1 polarization
of macrophages, whilst inhibiting the proliferation of Th2 cells and IL10 production, which
is consistent with our data. IFNγ also modulates CCL26 synthesis in human monocytic
cells, regulating inflammatory responses [21]. Upregulation of serum CCL27, as an inflam-
matory chemokine associated with the homing of memory T cells to sites of inflammation,
has recently been identified as an indicator for multiple sclerosis [22]. Our data combined
with that seen in multiple sclerosis research suggest that the inflammatory processes in SCI
lead to a systemic immune response that could potentially induce autoimmune responses
that closely resemble those in multiple sclerosis [23,24].
Our study found a positive association between SCI severity (AIS A) and CXCL5,
TNFα, CCL11, CXCL11, and IL10 concentration at 2 weeks post-SCI. At the same time, a
positive association in the MIF level was also observed in the AIS B patient group. Elevated
serum levels of TNFα in subacute and chronic SCI patients were observed by Davies et al.
(2007). However, this study did not draw an association with AIS grades, and unlike
our study, cytokine assessments were taken at different stages of SCI spread across 2 to
52 weeks post-injury and beyond 52 weeks. Another study found a negative correlation
between AIS improvement and TNFα serum levels at 9 h post-injury, but not during the
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subacute period [25]. Detection of IL10 concentration is often performed in CSF, but to
the best of our knowledge, there have been no reports of detectable levels of serum IL10
(<1 pg/mL) obtained from either controls or SCI subjects [26]. A pilot study reported by
Stein et al. (2013) showed the elevation of circulating MIF levels, but without a correlation
to AIS grades or injury regions in chronic SCI patients [27]. Our results demonstrate for the
first time a new set of cytokines (CXCL5, CCL11, and CXCL11) not previously described,
which have a potential role in SCI pathogenesis and can act as biomarkers of injury severity.
As a pilot study, our data is limited by patient number and these promising new findings
remain to be verified in a larger patient dataset.
We observed some potentially interesting trends when correlating SCI region with
blood serum cytokine levels. SCI in the C region had the greatest impact on the cytokine
profile in the blood serum, and associations with CXCL1, CXCL10, and CXCL11 concen-
trations were found. IFNγ has been found to be crucial for the induction of CXCL10 and
CXCL11 and the perpetuation of inflammation [28,29]. However, the level of IFNγ in our
study did not correlate with injury region. Recent evidence has also indicated that serum
expression of CXCL10 and CXCL11 is increased in multiple sclerosis patients and may
be involved in disease pathogenesis [30,31]. CXCL1 upregulation can contribute to the
maintenance of neuropathic pain and may play a critical role in stress-induced depression,
which can be observed predominantly in patients with SCI occurring in the C region [32,33].
Previously, it was reported that the concentrations of biomarkers detectable within
the CSF could be higher than the concentrations found within blood serum [12]. Com-
parative analysis of post-injury cytokine levels in both the CSF and blood serum at the
same time point would demonstrate if the use of blood serum, which has huge practical
advantages over CSF, could be used as an alternative fluid making fundamental changes
to the management of these patients. A retrospective comparative analysis of the data we
obtained from blood serum at 2 weeks post-injury with published CSF data is not possible
due to differences in experimental design and patient selection. To our knowledge, the only
study of 2 weeks post-injury CSF was conducted by Singh et al. (2016), which described an
elevated CSF concentration of nitric oxide within motor complete paraplegia/quadriplegia
SCI patients, compared to those with some spared motor function [17]. Other studies have
assessed the level of some cytokines within the CSF in traumatic brain injury (TBI) patients.
Of particular note, the work of Kumar et al. (2015) reconciles previously conflicting data
through its concurrent evaluation of CSF and serum [34]. The study identified two TBI
subpopulations with distinct CSF IL6 profiles—individuals in the high CSF temporal acute
IL6 trajectory (TRAJ) had higher mean subacute serum IL1b and IL6 levels compared with
the low TRAJ group.
In addition to cytokines, a small group of inflammatory proteins and trophic factors
are also under investigation as markers of SCI, including NSE and VEGF. An increase in
serum NSE concentration during the acute and subacute periods of SCI relative to controls
has already been reported [35,36]. Our data are consistent with these previous studies,
but go on to confirm that serum NSE does not appear to be a specific biomarker of injury
severity when compared to AIS groups. Schwartz et al. (2020) investigated a potential
association between muscle-based and serum biomarkers with pressure injury recurrence
following SCI [37]. They reported that serum VEGF was significantly increased in chronic
SCI patients who had never developed pressure injuries. To our knowledge, other studies
did not measure serum VEGF in SCI patients, and CSF concentrations of this growth factor
were not found to be of measurable levels using standard multiplex analysis [12]. Similarly,
our data did not show a significant elevation of serum VEGF concentration at 2 weeks
post-injury, including no difference between AIS grades.
5. Study Limitations
As this is a pilot study, there are several limitations that must be considered. First, the
limited patient sample size. Although our cohort of 28 SCI patients (at 2 weeks post-SCI)
is unevenly divided among AIS A and B severities, it is not the smallest patient cohort
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used for multiplex analysis of blood serum in this manner. Further testing of larger patient
cohorts, especially when balanced according to SCI region and AIS severity, is warranted
to ensure that the same findings are maintained. Second, uninjured controls are healthy
individuals without a history of traumas or musculoskeletal disease and were not exposed
to similar therapeutic regimes as the SCI patient group in this study. Further studies
to validate serum biomarkers should seek to eliminate possible treatment effects where
possible. Third, the single time point used in this study does not allow the tracing of
the kinetics of the changes. The addition of multiple time points would strengthen the
investigation and allow a more objective assessment of the changes.
6. Conclusions
To our knowledge, our study is the first report providing a unique description of
a number of inflammatory cytokines at 2 weeks post-SCI. The blood serum levels of
11 cytokines were significantly different at 2 weeks post-injury when compared to uninjured
controls. The levels of CXCL5, CCL11, CXCL11, IL10, TNFα, and MIF were expressed in
a severity-dependent fashion, whilst CXCL1, CXCL10, CXCL11, IL2, MIP-3a, MIG, and
CCL22 were expressed in a manner dependent upon the region of injury. Our pilot study
demonstrates the value of using blood serum concentrations of cytokines as a rapid and
affordable means of accurately classifying SCI severity in patients, removing the risks and
complications associated with a reliance on repeated CSF sampling.
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